Lupin bags USFDA approval for Mirabegron ER tablets to treat overactive bladder

The product will be manufactured at Lupin's facility in Nagpur, India.

Published On 2022-09-30 05:58 GMT   |   Update On 2022-09-30 05:58 GMT
Advertisement

Mumbai: Global pharma major Lupin Limited has announced that the Company has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Mirabegron Extended-Release Tablets, 25 mg, and 50 mg.

The product is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg, and 50 mg, of Astellas Pharma Global Development, Inc.

Advertisement

Mirabegron is indicated for treating the overactive bladder or neurogenic detrusor overactivity but does not cure these conditions.

Read also: Lupin unveils Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution in US

Overactive bladder occurs when you cannot control your bladder contractions. When these muscle contractions happen too often or cannot be controlled, you can get symptoms of overactive bladder, which are urinary frequency, urinary urgency, and urinary incontinence (leakage).

The product will be manufactured at Lupin's facility in Nagpur, India.

Mirabegron Extended-Release Tablets, 25 mg and 50 mg (RLD Myrbetriq), had estimated annual sales of USD 2403 million in the U.S. (IQVIA MAT June 2022).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas.

Read also: Lupin gets Health Canada nod for plaque psoriasis treatment Rymti

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News